The global market for pruritus therapies is segmented on the basis of drug type, disease, distribution channel and region. On the basis of drug type, the pruritus therapeutics market size is segmented into corticosteroids, antihistamines, local anesthetics, immunosuppressant, and others.
The corticosteroids segment generated highest revenue in 2021, owing to high prevalence rate throughout the world and resulting high demand for corticosteroids as treatment to cure pruritus. The corticosteroid segment was the largest segment in 2021, and is expected to grow at a CAGR of 4.4% during the forecast period. Furthermore, the others segment is expected to grow at a CAGR of 4.0% during the forecast period.
Request Report Sample - https://www.alliedmarketresearch.com/request-sample/17970
Pruritus, also known as itching, is a common symptom of many skin conditions and can be a frustrating and uncomfortable experience for patients.
While there is limited scientific evidence to support their effectiveness, some patients may find these therapies helpful.
The choice of therapy depends on the underlying cause of pruritus and the severity of symptoms. It is important to consult with a healthcare provider to determine the most appropriate treatment plan.
Procure Complete Report (246 Pages PDF with Insights, Charts, Tables, and Figures) @ https://www.alliedmarketresearch.com/checkout-final/1ca622c4486faf39c0c8d165c73b247d
Pruritus Therapeutics Market Players-
The key players operating in the global pruritus therapeutics market are
AbbVie Inc.,
Amgen Inc.,
Bausch Health Companies Inc.,
Cara therapeutics, Inc.,
Cipla Ltd.,
Eilly Lilly and Company,
Evelo Bioscience,
Galderma S.A.,
LEO Pharma,
MC2 Therapeuitics,
Novan Inc.,
Novartis AG,
Pfizer Inc.,
Regeneron Pharmaceuticals, Inc.,
Sanofi,
Trevi therapeutics.
and Viatris Inc.
A more significant underlying cause is typically indicated when pruritus persists for a longer time. On the basis of disease type, the global pruritus therapeutics market is divided into atopic dermatitis, allergic contact dermatitis, urticaria, and others. The atopic dermatitis segment is expected to grow at a CAGR of 3.2% during the forecast period. A heightened inflammatory response to a variety of potential irritants, such as dust, environmental pollutants, animals, certain foods, can cause eczema, which is also known as atopic dermatitis. The causes and prevalence of large number of the factors that lead to generation of the disease propels growth of the segment.
By distribution channels, the pruritus therapeutics market share market is divided into hospital pharmacies, drug store & retail pharmacies, and online providers. The drug stores & retail pharmacies segment is further divided, on basis of route of administration, into oral route, parenteral route, and topical route.
Connect to our analyst - https://www.alliedmarketresearch.com/connect-to-analyst/17970
Related Reports –
Vertigo Treatment Market- https://www.alliedmarketresearch.com/vertigo-treatment-market-A12485
Herpes Zoster Treatment Market - https://www.alliedmarketresearch.com/herpes-zoster-treatment-market-A13349
